Impact Story

Pharma companies want to identify and fund high-impact R&D, but risk aversion and scientific norms can prevent them from pursuing these transformational projects. Professor Josh Krieger explores the evaluation of early-stage ideas and how organizations can get lifesaving therapies in the R&D pipeline.